Tag: document

CALGARY, Alberta, July 22, 2025 (GLOBE NEWSWIRE) -- Pulse Seismic Inc. (TSX:PSD) (OTCQX:PLSDF) (“Pulse” or the “Company”) is pleased to report its financial and operating results for the three and six months ended June 30, 2025. The unaudited condensed consolidated interim financial statements, accompanying notes and MD&A are being filed on SEDAR+ (www.sedarplus.ca) and will be available on Pulse’s website at www.pulseseismic.com.

 iDox.ai launches iDox.ai Privacy Scout, an advanced AI-powered DLP solution that goes beyond blocking—enabling real-time data protection for safe, seamless document sharing with Generative AI.

Paris, le 22 juillet 2025

Paris, July 22^nd, 2025

SHANGHAI, July 22, 2025 (GLOBE NEWSWIRE) -- ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX”), a global mobility technology provider, today announced it has signed a strategic cooperation agreement with Monolithic Power Systems, Inc. ("MPS") (Nasdaq: MPWR), a fablite global company that provides high-performance, semiconductor-based power electronics solutions. The partnership will focus on collaboration in automotive intelligence and robotics and AI applications to establish a global supply chain and intelligent industrial ecosystem spanning system integration, platform adaptation, and delivery.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI^® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.